A pilot study assessing feasibility and usability of a mobile health tool on anticoagulation management for patients with atrial fibrillation
Latest Information Update: 28 Oct 2021
Price :
$35 *
At a glance
- Drugs Apixaban (Primary) ; Aspirin (Primary) ; Dabigatran etexilate (Primary) ; Edoxaban (Primary) ; Rivaroxaban (Primary) ; Warfarin (Primary)
- Indications Thromboembolism
- Focus Adverse reactions; Therapeutic Use
- 28 Oct 2021 New trial record
- 20 Oct 2021 Results published in the European Journal of Clinical Pharmacology